

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**December 2020**

---

**Commission File Number:** 0001723069

---

**Tiziana Life Sciences plc**  
(Exact Name of Registrant as Specified in Its Charter)

---

**3<sup>rd</sup> Floor,  
11-12 St James's Square  
London SW1Y 4LB  
United Kingdom**  
(Address of registrant's principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K**

On December 1, 2020, Tiziana Life Sciences plc (the “Company”) issued a regulatory news service announcement in the United Kingdom announcing an Investor Update Call on 2 December 2020 at 4:15 p.m. ET (the “RNS Announcement”).

The RNS Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**TIZIANA LIFE SCIENCES PLC**

Date: December 1, 2020

By: /s/ Kunwar Shailubhai

Name: Kunwar Shailubhai

Title: Chief Executive Officer

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	<a href="#">Regulatory News Service Announcement, dated December 1 2020</a>

**Tiziana Life Sciences to Host Investor Update Call  
on 2 December 2020 at 4:15 p.m. ET**

NEW YORK and LONDON – 1 December 2020 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA) (“**Tiziana**” or the “**Company**”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced its CEO and CSO Dr. Kunwar Shailubhai will host a conference call on Wednesday, 2 December 2020 at 4:15 p.m. ET to provide updates on the Company. Dr Shailubhai will provide updates on the Company’s proposed move from AIM to the Standard Segment of the Main Market of the London Stock Exchange, ongoing clinical trials, as well as other recent developments in Tiziana Life Sciences.

**Date:** Wednesday, 2 December 2020  
**Time:** 4:15 p.m. Eastern Time  
**Live Call:** +1-877-425-9470 (U.S. Toll-Free) or +1-201-389-0878 (International)  
**Webcast:** <http://public.viavid.com/index.php?id=142634>

For interested individuals unable to join the conference call, a dial-in replay of the call will be available until 16 December 2020 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 13713850.

**About Tiziana Life Sciences**

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn’s disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

**For further enquiries:**

United Kingdom Investors:  
**Tiziana Life Sciences plc** +44 (0)20 7495 2379  
 Gabriele Cerrone, Chairman and founder

United States Investors:  
 Dave Gentry Office 1 800 RED CHIP (733 2447)  
 RedChip Companies Inc. Cell 407-491-4498 (USA)  
 dave@redchip.com